Solid Biosciences Provides Data Update from SGT-001 Development Program

CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced biomarker data from two patients dosed in the second cohort of IGNITE DMD, its Phase I/II study of SGT-001.